Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Go back to Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 79.55 +0.38 (0.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.17 | 52 Week High | $13.18 | |||
| Open | $78.99 | 52 Week Low | $6.00 | |||
| Day High | $80.40 | P/E | N/A | |||
| Day Low | $78.27 | EPS | $-1.24 | |||
| Volume | 1,219,097 | |||||
